Hospira Recalls Dacarbazine Vials Due to Discoloration
Hospira Inc. recalls specific lots of Dacarbazine Injection, USP 200mg vials due to potential pink discoloration. Check lot numbers and expiration dates.
Use caution until it’s fixed
Discoloration: Reconstituted solution may appear pink instead of colorless to pale yellow when stored per the labeled conditions.
Contact the company
What happened, in plain English
Hospira Inc. is recalling 3,306 vials of Dacarbazine, Injection, USP 200mg because the reconstituted solution may appear pink instead of its normal colorless to pale yellow appearance when stored as labeled. This specific batch was manufactured in Australia and distributed nationwide. The recall affects a Class III product, which typically indicates a hazard that is unlikely to cause serious adverse health consequences but could still pose risks depending on usage. Read more at govinfonow.com/recall/45144-hospira-inc-recalls-dacarbazine-injection-usp-200mg-vials-packaged-in.
Source Summary by GovInfoNow · govinfonow.com/recall/45144-hospira-inc-recalls-dacarbazine-injection-usp-200mg-vials-packaged-in · Updated October 12, 2026 · FDA enforcement record: FDA #D-0313-2015
Cite this page
“Hospira Recalls Dacarbazine Vials Due to Discoloration.” GovInfoNow, updated October 12, 2026. https://govinfonow.com/recall/45144-hospira-inc-recalls-dacarbazine-injection-usp-200mg-vials-packaged-in. Based on FDA recall #D-0313-2015 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0313-2015%22&limit=1).
Why it’s dangerous
The primary hazard is a visual change in the drug's appearance; the reconstituted solution may turn pink instead of remaining colorless to pale yellow. While the record does not explicitly state that the discoloration renders the drug ineffective or toxic, such changes in pharmaceutical products can indicate stability issues or contamination, necessitating caution before administration.
Who’s affected
Patients receiving chemotherapy who have been prescribed Dacarbazine Injection, USP 200mg from the specific recalled lots. Healthcare providers administering this medication are also directly affected.
How to tell if you have this one
Look for Dacarbazine, Injection, USP 200mg vials manufactured by Hospira Australia. Specifically check for NDC 61703-327-22 and Lot # B032223AA with an expiration date of July 2016.
- Brand
Hospira- Category
Drug
What to do — step by step
Check Inventory
Verify if you have vials matching NDC 61703-327-22, Lot # B032223AA, expiring in July 2016.
Contact Provider
If you have the recalled product, contact your healthcare provider or pharmacist for instructions on return or disposal.
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “Nationwide” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 2.1 years after the firm started it.
- Firm started the recall
- FDA classified it Class III
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0313-2015 (November 25, 2014) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0313-2015 to see it in context.
- Plain-language summary written by qwen3.6:35b-a3b on October 12, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.